info@athenex.com716.427.2950
AthenexAthenex
Athenex
Improving the lives of cancer patients everywhere
  • About
    • About Athenex
    • Our Other Companies
    • Our Partnerships
  • Oncology Innovation
    • Orascovery Platform
    • Src Kinase Inhibition
    • Dual Inhibition
    • Clinical Trials
  • Operating Platforms
    • Commercial Segment
    • Internal Supply Chain
  • Our Team
    • Our Board of Directors
    • Our Leadership Team
    • Other Key Employees
    • Our Advisors
  • Careers
  • Investor Relations
    • Overview
    • Stock Information
      • Stock Quote & Chart
      • Historical Price Lookup
      • Investment Calculator
      • Analyst Coverage
    • News & Events
      • Press Releases
      • Investor Calendar
      • Presentations
    • Financial Information
      • SEC Filings
      • Annual Meeting Materials
      • Annual Reports
      • Quarterly Results
    • Corporate Governance
      • Governance Highlights
      • Committee Composition
    • Investor Resources
      • Investor FAQs
      • Information Request
      • E-mail Alerts
      • IR Contacts
Menuback 
 

Event Details

Q1 2018 Athenex, Inc. Earnings Conference Call

Monday, May 14, 2018 9:00 a.m. ET  

Webcast Presentation

Click here for webcast
Event Details
Title
Q1 2018 Athenex, Inc. Earnings Conference Call
Date / Time
May 14, 2018 9:00 a.m. ET
Unauthorized recording or downloading of this event is not permitted.
 
 
  • Print Page Print Page
  • E-mail Page E-mail Page
  • RSS RSS
  • E-mail Alerts E-mail Alerts
  • Tearsheet Tearsheet
Athenex - Improving the lives of cancer patients everywhere
Learn More
Our Company

Athenex is an innovative oncology company with drug discovery, drug formulation, clinical development, and API/drug product manufacturing facilities in both the U.S. and China. Our mission is to improve the lives of cancer patients by creating more effective, safer and tolerable treatments.

Other Athenex Companies

Polymed Therapeutics
Athenex Pharma Solutions
CDE

Learn More

Contact Us

North American Headquarters


Conventus Building
1001 Main Street
Suite 600
Buffalo, New York 14203

P: (1) 716.427.2950
F: (1) 716.800.6816
E: info@athenex.com

Asia Headquarters


Unit 608-613, IC Development Centre,
No. 6 Science Park West Avenue,
Hong Kong Science Park, Sha Tin, New Territories, Hong Kong

P: (852) 2607.4100
F: (852) 3996.7454

Other Athenex Addresses

Athenex Pharmaceutical Division
10 N. Martingale Road, Suite 230
Schaumburg, IL 60173

Athenex New Jersey
20 Commerce Drive, Suite 100
Cranford, NJ 07016

Polymed Therapeutics
3040 Post Oak Blvd., Suite 110
Houston, TX 77056

Chongqing Taihao Pharmaceutical
C-5 #105 C-5, Er Lang Chuang Ye Road,
Jiulongpo District, Chongqing, China

News & Press
  • Athenex, Inc. to Report Fourth Quarter and Fiscal Year 2018 Earnings Results on March 11, 2019
    February 14, 2019
  • Athenex Announces Late-Breaking Oral Presentation of KX2-391 Ointment in Two Phase III Studies at the American Academy of Dermatology Annual Meeting
    February 04, 2019
  • Athenex Announces Completion of Target Enrollment in the Oraxol Phase III Study
    January 09, 2019

© Athenex, Inc. All rights reserved

  • Home
  • About Us
  • Oncology Innovation
  • Operating Platforms
  • Our Team
  • Careers
  • Investor Relations
  • Contact Us
Footer Menu